# Metagenomi Therapeutics, Inc. (MGX) stock price

URL: https://funkfolio.com/stock/MGX

> Metagenomi Therapeutics, Inc. (MGX) trades at $0.63, is worth $23.86M and scores 36/100. Valuation, financials and signals.

---

## Metagenomi Therapeutics, Inc. (MGX)

Metagenomi Therapeutics, Inc. (MGX) is a healthcare company (biotechnology) based in the United States. The share price is $0.63, down 7.21% on the day, which values the company at $23.86M. Price as of 18 Nov 2026, 09:07 UTC, from Yahoo Finance.

### Key facts

- **Share price:** $0.63 −7.21% today
- **Market value:** $23.86M
- **Funk Score:** 36/100
- **Sector:** Healthcare

Figures as of 18 Nov 2026, 09:07 UTC. Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

### Metagenomi Therapeutics, Inc. in more detail

MGX trades at -0.3× next year's expected earnings, 3.4× sales.

Its Funk Score is 36 out of 100 (financial strength 3.8, profitability 0.0, growth 6.9, each out of 10).

In its favour: More cash than debt. Worth checking: Altman Z in the distress zone; Weak Piotroski score.

### Metagenomi Therapeutics, Inc. (MGX): questions and answers

**What is Metagenomi Therapeutics, Inc.'s market cap?**

Metagenomi Therapeutics, Inc. is valued at $23.86M at a share price of $0.63.

**How fast is Metagenomi Therapeutics, Inc. growing?**

Over the last three fiscal years Metagenomi Therapeutics, Inc.'s revenue grew 13.6% a year.

**Does MGX pay a dividend?**

Metagenomi Therapeutics, Inc. does not currently pay a regular dividend.

### Learn to read these numbers

[All stocks guides →](https://funkfolio.com/learn/stocks)

- [Altman Z-score: formula, zones and where it fails](https://funkfolio.com/learn/stocks/altman-z-score)

  The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- [Analyst price targets and ratings: what they mean](https://funkfolio.com/learn/stocks/analyst-price-targets)

  An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- [Free cash flow and FCF yield explained](https://funkfolio.com/learn/stocks/free-cash-flow)

  Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.

### Cite this page

Funkfolio, “Metagenomi Therapeutics, Inc. (MGX) stock: price, valuation and fundamentals”, data as of 18 November 2026. https://funkfolio.com/stock/MGX

Underlying data: Yahoo Finance; company filings with the SEC.
